SCHEMBL695239

SCHEMBL695239

Cc1cc(N2C[C@H](S(C)(=O)=O)C[C@H]2C(=O)O)n(-c2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.38
PHGDH O43175 1/20 0.35
PTGS2 P35354 5/20 0.35
EPHX2 P34913 2/20 0.35
CRHR1 P34998 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
TSHR P16473 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CTSS P25774 4/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
CHRNA7 P36544 1/20 0.34
PTGS1 P23219 1/20 0.34
CTSL P07711 2/20 0.33
CTSB P07858 2/20 0.33
CTSK P43235 2/20 0.33
S1PR1 P21453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL696422 0.90 SMN1; SMN2 (0.41) PTGS2EPHX2CRHR1KDM4ECYP3A4
SCHEMBL2105284 0.90 SMN1; SMN2 (0.41) PTGS2EPHX2CRHR1KDM4ECYP3A4
SCHEMBL695506 0.89 ELOVL6 (0.43) NOTUMPTGS2EPHX2TSHRALDH1A1
SCHEMBL694118 0.87 CRHR1 (0.39) NOTUMPHGDHEPHX2CRHR1KDM4E
SCHEMBL15327758 0.87 CRHR1 (0.39) NOTUMPHGDHEPHX2CRHR1KDM4E
SCHEMBL696030 0.86 CTSS (0.45) CRHR1ALDH1A1CTSSCTSLCTSB
SCHEMBL3064969 0.86 CTSS (0.51) CTSSCTSLCTSBCTSK
SCHEMBL696805 0.84 CTSS (0.50) CTSSCTSLCTSBCTSK
SCHEMBL696305 0.84 CTSS (0.51) CTSSCTSL
SCHEMBL3064323 0.80 CTSS (0.41) CTSSCTSLCTSBCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP claimed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US claimed
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 NOTUM 2571/4885PHGDH 598/4885PTGS2 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.